U.S. Markets closed

Celsion Corporation (CLSN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2351-0.01 (-5.96%)
At close: 4:00PM EDT

0.2387 -0.00 (-0.04%)
After hours: 5:53PM EDT

People also watch
DCTHCYCCCPRXAVEOTHLD
  • Imagehumphidk
  • They plan on raising $25M or, with discounted share pricing, 2X the current market cap. Anyone owning shares will see their stake in the company drop to 1/3 of the current pct. Due to past bad management they really don't have a choice but, does it ever suck to be a CLSN shareholder
  • CLSN -- Buy more or sell what I got.?????
  • The five grand i paid for this stock a couple years ago is now worth 168 dollars. It will be a write off for this year.
  • Any news about earnings??
  • I think CLSN is due for a pullback. What are your thoughts? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from a.awesomestocks.
  • Deregulation executive order coming for bio? Would this stock pop then?
  • Drop CLSN and put it on watchlist for now. R/S will likely occur this year it was put to vote already. NVAX may be more interesting.
  • recently received classic line cold call pitch -
    "we once discussed celsion, today I want to introduce you to a real company"
  • Are the chances of CLSN meeting it's Q1 estimates pretty good?
  • What is RS?
  • they'll run it up to 60 cents for the RS , get max bang for the shorts once it RS's .... they want to RS it as high as possible so the shorting makes huge profits
  • Wish the 21stCCA & THE SBIR would get involved!!!!!

    http://finance.yahoo.com/news/celsion-corporation-reports-preclinical-results-123000176.html

    The study was conducted under a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to evaluate whether ThermoDox® combined with mild heating of the bladder can target drug delivery in the bladder.

    The NIH studies were conducted under the direction of Dr. Bradford Wood, MD, Director, NIH Center for Interventional Oncology and Chief, NIH Clinical Center Interventional Radiology

    WISHES FOR HORSES,,, OR MAYBE NOT !!!!!

    Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia
    Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved with ThermoDox ® Combined with Mild Local Hyperthermia Compared to Free Doxorubicin Alone. The Study ...
    finance.yahoo.com
  • CLSN - hsbc trading showing 1.50 target price? Adding to watchlist. Not familar with this one but chart shows potential.
  • CBLI
    Cleveland BioLabs, Inc. 4.80 3.24 207.69%
  • Well MT...Time to pull the partnership out of your hat...The one you've been hinting at for years...What happened to those "chills" you mentioned you were getting from the read-outs? Are you in cahoots with your banker friends? Pushing to a R/S? Do they have you by the B@%!&? Have you called the SEC like any good CEO would do? Complaining about the naked shorting! Time to put up or...You know the rest...
  • NEXT BUYOUT TARGET HERE
    AQSZF (MC $15 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $15 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 15 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.21

    MUST WATCH to realize the MONSTER POTENTIAL HERE
    https://www.youtube.com/watch?v=jV00WmYBtv4

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    AQS1301 topline results in 1Q 2017

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

    Aequus Pharmaceuticals
    Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
    www.youtube.com
  • If you tell the truth you don't have to remember anything. http://dataunion.tistory.com/1523

    [2016-MAY] Celsion Corporation NASDAQ : CLSN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • why is it holding at .27 .30 range , I don't see any short term catalyst !! I was expecting to go below .23..
  • penetrating China and Vietnam, big markets began trails, prominent forecast